ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

28 May 2021 07:05:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Reports First Quarter 2021 Financial Results

27 May 2021 16:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27

17 May 2021 16:05:02 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan

12 May 2021 16:28:15 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile

10 May 2021 17:17:47 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH at Upcoming Medical Conferences

06 May 2021 16:05:01 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Participation at the BofA Securities 2021 Virtual Health Care Conference

04 May 2021 16:05:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences

21 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum

30 Mar 2021 07:05:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021

23 Mar 2021 07:05:00 By Nasdaq GlobeNewswire